Anti-OAS1 Polyclonal Antibody for WB, ELISA - P00973

Core Product Specifications and Parameters

Biological Background: OAS1 Function and Localization

• The OAS1 gene encodes 2'-5'-oligoadenylate synthase 1, with multiple isoforms (p46/p42) produced via alternative splicing, which differ in C-terminal prenylation and subcellular localization.
• As an interferon-induced, dsRNA-activated enzyme, OAS1 catalyzes the synthesis of 2'-5'-oligoadenylates (2-5A) from ATP; these activate RNase L, leading to RNA degradation and inhibition of protein synthesis, thereby terminating viral replication. Related references: PMID:34145065, PMID:34581622, PMID:40010341
• OAS1 can mediate antiviral effects through both RNase L-dependent and independent pathways; the secreted form exhibits activity against VSV, HSV-2, and EMCV. Related references: PMID:34145065, PMID:34581622, PMID:40010341
• Prenylated OAS1 specifically targets SARS-CoV-2 replication organelles, binding dsRNA structures in the 5'-UTR and blocking viral replication. Related references: PMID:34581622
• OAS1 is found in multiple subcellular compartments including cytoplasm, mitochondria, nucleus, ER, and microsome, and can be secreted, with prenylation directing membrane localization.
• The protein is expressed in lungs, suggesting a role in respiratory pathogen defense.
• OAS1 belongs to the 2-5A synthetase family, characterized by nucleotidyltransferase activity, ATP and RNA binding, and a central role in innate antiviral immunity.
• Genetic variants of OAS1 are associated with immunodeficiency IMD100, and the protein is extensively identified in proteomics studies.

Experimental Guidance and Technical Tips

• The antibody was raised against a recombinant protein encompassing amino acids 1–364 of human OAS1, covering the catalytic domain; consider that it may detect multiple isoforms and prenylated variants.
• For Western blot analysis, use interferon-stimulated human cell lines (e.g., A549, HeLa) or lung tissue lysates as positive controls; optimize loading and antibody dilution empirically.
• In ELISA applications, validate the antibody with recombinant OAS1 protein or extracts from treated cells, and include appropriate negative controls.
• Cross-reactivity with mouse OAS1 is reported; verify sequence homology and performance in the intended species to ensure specificity.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio serves as a comprehensive IVD raw-material partner, connecting diagnostic manufacturers and labs with high-quality reagents from discovery through commercialization. Our portfolio includes validated antibody pairs, optimized polyclonal and monoclonal antibodies, and bulk ancillary reagents tailored for innate immunity and antiviral research—accelerating development of assays for targets like OAS1. By handling sourcing, supply chain logistics, and technical support, CamelBio ensures seamless access to rare and established raw materials, empowering your projects from concept to clinic.